Bryan Stuart is the former President and CEO of Fulcrum Therapeutics, where he held the position from March 2021 to January 2023. He has a solid academic background, holding an MBA from the Kellogg School of Management at Northwestern University...

Bryan Stuart is the former President and CEO of Fulcrum Therapeutics, where he held the position from March 2021 to January 2023. He has a solid academic background, holding an MBA from the Kellogg School of Management at Northwestern University and a B.S. from the University of Illinois. Before stepping up to lead Fulcrum, Bryan served as Chief Operating Officer and held CEO roles at two other biotech firms focused on rare diseases. His tenure at Fulcrum saw the company focus on developing therapies for serious medical conditions. Interestingly, in 2022, he received a total compensation of about $792,450, but he did not receive additional bonuses for 2023 due to transitioning out of his role. His time as CEO coincided with significant fluctuations in stock trading, where he notably made trades valued at millions of dollars, showcasing his financial involvement with the company. Despite his departure, his legacy includes a focus on aligning leadership with the company's performance and a commitment to driving innovative solutions in the biotech space.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Fulcrum Therapeutics, Inc. CEOs

F

Bryan Stuart

Ex-CEO of Fulcrum Therapeutics, Inc.

Education

MBA from Kellogg School of Management at Northwestern University, B.S. from University of Illinois.

Field of Expertise

Business & Management

Sector of Economy

Healthcare

Born

January 1, 1979 - 46 years ago

CEO of Fulcrum Therapeutics, Inc. for

1 year 9 months (Mar 2021 - Jan 2023)

Previous Experience

CEO of Yarra Therapeutics, LLC; CEO of Kastle Therapeutics, LLC; Chief Business Officer at Civitas Therapeutics, Inc.

Rivals

Competitors/colleagues of Bryan Stuart

Holdings

See how much did Bryan Stuart make over time.

Bryan Stuart had significant holdings in Fulcrum Therapeutics, with insider trading activity showing peaks and valleys. At one point in 2021, his holdings were valued as high as $6.80 million. Over time, these values fluctuated, tapering down by early 2023,...

Bryan Stuart had significant holdings in Fulcrum Therapeutics, with insider trading activity showing peaks and valleys. At one point in 2021, his holdings were valued as high as $6.80 million. Over time, these values fluctuated, tapering down by early 2023, as he transitioned out of his CEO role. His trading activity during these times indicates his deep involvement with the company's stock, reflecting both his confidence in the company's direction and the risks associated with such positions. By late 2022, his trading volumes had decreased, suggesting a strategy shift following his leadership evolution. Even as he left Fulcrum, his trading behavior and holdings embodied a dynamic approach to managing personal equity in a challenging biotech landscape.

Loading...

Total Stock Sold

$1.17M

FULC

$1.17M

60,000 FULC shares

What if they kept their stock?

If Bryan Stuart didn't sell their stock, today they would have:
Extra FULC60,000 shares worth $1.06M.
This is -9.3% and $108.44K less than what they got when they sold the stock.

Insider Trading

See recent insider trades of Bryan Stuart.

FULC

$1.24M

FULC at $20.63/share

Aug 10, 2021

Sale

Compensation History

See how much did Bryan Stuart make over time.

In 2022, Bryan Stuart's total compensation was $792,450, which included a salary of $572,450 and a performance-based bonus of $220,000. Notably, he received no bonuses in 2023, as his role was ending. His peak earnings during his time at Fulcrum reflected the company's strategic goals aimed at innovation and development in rare diseases. As CEO, he managed to earn a significant portion of his compensation through performance metrics tied to the company’s success, aligning his financial incentives with company outcomes. However, his transition in early 2023 hinted at a reshuffle of leadership and strategy, with a severance agreement that ensured he received benefits tied to his previous contributions, even after leaving the role.

Year

2023

Total Compensation

$574.84K

Salary

$2.39K

Board Justification

The company aims to align executive compensation with performance and market standards, ensuring retention and motivation of key executives.

Bonus

$0.00

Board Justification

Mr. Stuart was not eligible for a 2023 bonus given his January 2023 separation from service.

Other

$572.45K

Board Justification

Reflects severance benefits in connection with his January 2023 separation from service.

Restricted Stock

$0.00(0 common stock)

Board Justification

No stock was vested in 2023 as he transitioned out of his role in January 2023.

Performance Metrics

No performance metrics were applicable for 2023 due to Mr. Stuart's separation from service.

Other Fulcrum Therapeutics, Inc. CEOs

Here are other CEOs of Fulcrum Therapeutics, Inc.

Robert J. Gould

Ex-CEO of Fulcrum Therapeutics, Inc.

July 2021 - March 2021